Advertisement
Advertisement

KZR

KZR logo

Kezar Life Sciences, Inc. Common Stock

6.03
USD
Sponsored
-0.14
-2.35%
Jan 30, 10:00 UTC -5
Open

KZR Earnings Reports

Positive Surprise Ratio

KZR beat 23 of 30 last estimates.

77%

Next Report

Date of Next Report
Mar 23, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$1.24
Implied change from Q3 25 (Revenue/ EPS)
--
/
-18.95%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-55.23%

Kezar Life Sciences, Inc. Common Stock earnings per share and revenue

On Nov 12, 2025, KZR reported earnings of -1.53 USD per share (EPS) for Q3 25, beating the estimate of -2.09 USD, resulting in a 27.09% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.16% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -1.24 USD, with revenue projected to reach -- USD, implying an decrease of -18.95% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q3 2025, Kezar Life Sciences, Inc. Common Stock reported EPS of -$1.53, beating estimates by 27.09%, and revenue of $0.00, 0% as expectations.
The stock price moved down -0.16%, changed from $6.16 before the earnings release to $6.15 the day after.
The next earning report is scheduled for Mar 23, 2026.
Based on 6 analysts, Kezar Life Sciences, Inc. Common Stock is expected to report EPS of -$1.24 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement